Active Awards Portfolio Dashboard
It takes a lot of effort to develop a promising stem cell research idea into an effective treatment that can help patients. CIRM funds a pipeline of projects spanning discovery, translation and clinical stage research. Check out our portfolio of active research awards in our interactive dashboard below. For a detailed list of CIRM-funded clinical trials, visit our Clinical Trials Dashboard.

Filter Awards
Disease | Cell Type | Therapeutic or Technology | Institution | Stage | Project Objective | Details |
---|---|---|---|---|---|---|
Sickle Cell Disease | Adult Stem Cell | Donor cell therapy | ExCellThera Inc. |
![]() |
Clinical Trial, Phase 1 or Phase 1/2 | |
Blood Disorders, Immune Disease |
Adult Stem Cell | Gene-modified, personalized cell therapy | UCLA |
![]() |
Proof of Concept | |
COVID-19 | Adult Stem Cell | Small molecule therapy | Stanford |
![]() |
Development Candidate, Proof of Concept | |
COVID-19 | Adult Stem Cell | Vaccine | Stanford |
![]() |
Development Candidate, Proof of Concept | |
COVID-19 | Adult Stem Cell | Gene-modified, donor cell therapy | COH |
![]() |
Development Candidate, Proof of Concept | |
COVID-19 | Adult Stem Cell | Vaccine | UCLA |
![]() |
Development Candidate, Proof of Concept | |
COVID-19 | Adult Stem Cell | Small molecule therapy | UCLA |
![]() |
Pre-IND/IDE or Equivalent | |
COVID-19, Respiratory Disorders |
Adult Stem Cell | Donor cell therapy | Celularity Inc |
![]() |
Clinical Trial, Phase 1 or Phase 1/2 | |
COVID-19, Respiratory Disorders |
iPS Cell | Gene-modified, donor cell therapy | USC |
![]() |
Development Candidate, Proof of Concept | |
COVID-19, Respiratory Disorders |
iPS Cell | Small molecule therapy | Sanford-Burnham |
![]() |
Development Candidate, Proof of Concept | |
COVID-19 | iPS Cell | Cell delivery or targeting | UCSD |
![]() |
Tool/Resources/Bottleneck | |
Epilepsy | Embryonic Stem Cell | Donor cell therapy | Neurona Therapeutics |
![]() |
Research Insights | |
COVID-19, Respiratory Disorders |
Adult Stem Cell | Biologic | UCSD |
![]() |
Development Candidate, Proof of Concept | |
COVID-19 | Adult Stem Cell | Gene-modified, donor cell therapy | UCLA |
![]() |
Development Candidate, Proof of Concept | |
Severe Combined Immunodeficiency, X-linked (X-SCID) | Adult Stem Cell | Antibody | Jasper Therapeutics, Inc. |
![]() |
Clinical Trial, Phase 1 or Phase 1/2 | |
Traumatic Brain Injury | Embryonic Stem Cell | Exosomes based therapy | UC Irvine |
![]() |
Development Candidate, Proof of Concept, Research Insights | |
Skeletal/Smooth Muscle disorders | Adult Stem Cell | Small molecule therapy | Stanford |
![]() |
Proof of Concept | |
HIV/AIDS, Immune Disease |
Adult Stem Cell | Gene-modified, personalized cell therapy | UCSF |
![]() |
Clinical Trial, Phase 1 or Phase 1/2 | |
Bone or Cartilage Disease | Adult Stem Cell | Gene-modified, personalized cell therapy | Rocket Pharmaceuticals, Inc. |
![]() |
Clinical Trial, Phase 1 or Phase 1/2 | |
Spina Bifida | Adult Stem Cell | Donor cell therapy | UC Davis |
![]() |
Clinical Trial, Phase 1 or Phase 1/2 | |
Ovarian Cancer | iPS Cell | Gene-modified, donor cell therapy | UCSD |
![]() |
Development Candidate, Proof of Concept | |
Blood Disorders | Adult Stem Cell | Gene-modified, personalized cell therapy | UCLA |
![]() |
Development Candidate, Proof of Concept | |
Type 1 diabetes | Embryonic Stem Cell | Gene-modified, donor cell therapy | Lundquist Institute |
![]() |
Development Candidate, Proof of Concept | |
Inflammatory bowel disease | Adult Stem Cell | Donor cell therapy | Vitabolus, Inc. |
![]() |
Development Candidate, Proof of Concept | |
Neurological Disorders | Embryonic Stem Cell | Donor cell therapy | UC Irvine |
![]() |
Development Candidate, Proof of Concept | |
Amyotrophic Lateral Sclerosis | iPS Cell | Nucleic acid based therapy | USC |
![]() |
Development Candidate, Proof of Concept | |
Traumatic Brain Injury | iPS Cell | Donor cell therapy | UC Irvine |
![]() |
Development Candidate, Research Insights | |
Stroke | iPS Cell | Donor cell therapy | UCLA |
![]() |
Development Candidate, Proof of Concept | |
COVID-19 | iPS Cell | Small molecule therapy | UCSD |
![]() |
Development Candidate, Proof of Concept | |
COVID-19 |
Embryonic Stem Cell, iPS Cell |
Gene-modified, donor cell therapy | COH |
![]() |
Proof of Concept | |
Sickle Cell Disease | Adult Stem Cell | Gene-modified, personalized cell therapy | Boston Children's Hospital |
![]() |
Clinical Trial, Phase 2 | |
Spinal Cord Injury | Embryonic Stem Cell | Therapeutic Approach | UCSD |
![]() |
Development Candidate, Research Insights | |
COVID-19 | iPS Cell | Model system development | UC Berkeley |
![]() |
Proof of Concept | |
Beta Thalassemia, Sickle Cell Disease |
Adult Stem Cell | Diagnostic Test | UCSF |
![]() |
Regulated Lab Test, Ready for Validation |
Pages
- « first
- ‹ previous
- 1
- 2
- 3